The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 11, 2020

Filed:

Feb. 11, 2017
Applicants:

Invictus Oncology Pvt. Ltd., Delhi, IN;

The Brigham and Women's Hospital, Inc., Boston, MA (US);

Inventors:

Monideepa Roy, Andover, MA (US);

Goutam Biswas, Delhi, IN;

Hemant Suryavanshi, Delhi, IN;

Anubhab Mukherjee, Delhi, IN;

Ashish Kulkarni, Arlington, MA (US);

Shiladitya Sengupta, Philadelphia, PA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/54 (2017.01); C07J 41/00 (2006.01); C07D 417/12 (2006.01); C07J 43/00 (2006.01); C07J 9/00 (2006.01); A61K 47/69 (2017.01); A61K 47/55 (2017.01); A61P 35/00 (2006.01); A61K 31/4439 (2006.01); A61K 31/575 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 47/554 (2017.08); A61K 31/4439 (2013.01); A61K 31/575 (2013.01); A61K 45/06 (2013.01); A61K 47/545 (2017.08); A61K 47/55 (2017.08); A61K 47/6929 (2017.08); A61P 35/00 (2018.01); C07D 417/12 (2013.01); C07J 9/00 (2013.01); C07J 41/0005 (2013.01); C07J 41/0055 (2013.01); C07J 41/0088 (2013.01); C07J 43/003 (2013.01);
Abstract

The present disclosure relates generally to Cellular Signalling inhibitors of compound of Formula I, compositions and formulations comprising the same, methods, processes, and uses thereof. In particular, the present disclosure provides CSF-1R inhibitors demonstrating sustained inhibition of CSF/CSF1R signalling pathway with decreased toxicity. The present disclosure also provides supramolecular combinatorial therapeutics, wherein a CSF-1R inhibitor is combined with one or more of a chemotherapeutic agent, a kinase inhibitor, and an immunoregulator, each of which is optionally conjugated with a lipid. The present disclosure also provides a method for treating cancer, allergy, Systemic lupus erythematosus, nephritis, Chronic Obstructive Pulmonary Disease, and abnormal macrophage functions or any combinations thereof.


Find Patent Forward Citations

Loading…